• argenx published its annual report on Form 20-F for the fiscal year ended Dec. 31, 2025.
• Product net sales rose 90% to USD 4.15 billion, reflecting higher VYVGART sales in the U.S. and other countries as the company expanded global commercialization and obtained additional approvals.
• Other operating income increased 46% to USD 96.73 million, mainly due to R&D tax incentives, payroll tax rebates and clinical supply of product tied to VYVGART product net sales in Greater China through Zai Lab.
• Operating profit was USD 1.05 billion and profit for the year increased 55% to USD 1.29 billion.
• Management said it expects operating expenses to increase as it advances registrational and proof-of-concept studies across efgartigimod, empasiprubart and adimanebart and continues commercial expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001697862-26-000032), on March 19, 2026, and is solely responsible for the information contained therein.